As August 5 approaches, Amgen (AMGN) gears up to reveal its Q2 2025 earnings after market close, and expectations are high ...

The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR ...

Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS ...

Insmed, a biopharmaceutical specialist in rare diseases, is stealing the spotlight in 2025 with a stunning 62% gain, ...

Valley Wealth Managers Inc. just upped their Amgen game by 8.1% this quarter, now holding a cool $27.15 million worth of ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

This was the stock's third consecutive day of losses.

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for ...